Progyny, Inc. (NASDAQ:PGNY) Director Sells $387,511.60 in Stock

Progyny, Inc. (NASDAQ:PGNY) Director Norman Payson sold 8,330 shares of the company’s stock in a transaction that occurred on Wednesday, January 12th. The shares were sold at an average price of $46.52, for a total value of $387,511.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Norman Payson also recently made the following trade(s):

  • On Wednesday, January 5th, Norman Payson sold 8,330 shares of Progyny stock. The shares were sold at an average price of $46.99, for a total value of $391,426.70.
  • On Wednesday, December 22nd, Norman Payson sold 8,330 shares of Progyny stock. The shares were sold at an average price of $50.62, for a total value of $421,664.60.
  • On Wednesday, December 15th, Norman Payson sold 8,330 shares of Progyny stock. The shares were sold at an average price of $47.60, for a total value of $396,508.00.
  • On Wednesday, December 8th, Norman Payson sold 8,330 shares of Progyny stock. The shares were sold at an average price of $50.65, for a total value of $421,914.50.
  • On Wednesday, December 1st, Norman Payson sold 8,330 shares of Progyny stock. The shares were sold at an average price of $50.13, for a total value of $417,582.90.
  • On Tuesday, November 23rd, Norman Payson sold 8,130 shares of Progyny stock. The stock was sold at an average price of $54.26, for a total value of $441,133.80.
  • On Wednesday, November 17th, Norman Payson sold 8,330 shares of Progyny stock. The stock was sold at an average price of $63.36, for a total value of $527,788.80.
  • On Wednesday, November 10th, Norman Payson sold 8,330 shares of Progyny stock. The stock was sold at an average price of $63.18, for a total value of $526,289.40.
  • On Wednesday, November 3rd, Norman Payson sold 8,330 shares of Progyny stock. The stock was sold at an average price of $61.40, for a total value of $511,462.00.
  • On Wednesday, October 27th, Norman Payson sold 8,330 shares of Progyny stock. The stock was sold at an average price of $60.69, for a total value of $505,547.70.

Progyny stock opened at $43.19 on Friday. The firm’s 50 day simple moving average is $51.97 and its 200-day simple moving average is $55.01. The company has a market cap of $3.91 billion, a P/E ratio of 47.99 and a beta of 1.72. Progyny, Inc. has a fifty-two week low of $38.61 and a fifty-two week high of $68.32.

Progyny (NASDAQ:PGNY) last released its earnings results on Thursday, November 4th. The company reported $0.17 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.11. Progyny had a net margin of 18.96% and a return on equity of 29.67%. The business had revenue of $122.30 million for the quarter, compared to the consensus estimate of $125.52 million. During the same period last year, the firm posted $0.05 earnings per share. The firm’s quarterly revenue was up 23.7% compared to the same quarter last year. As a group, research analysts predict that Progyny, Inc. will post 0.54 earnings per share for the current fiscal year.

PGNY has been the subject of several recent analyst reports. Citigroup cut Progyny from a “buy” rating to a “neutral” rating and increased their price target for the stock from $60.00 to $64.00 in a research note on Monday, November 22nd. Berenberg Bank began coverage on shares of Progyny in a research report on Thursday, September 30th. They issued a “buy” rating and a $81.00 target price for the company. JPMorgan Chase & Co. boosted their price target on shares of Progyny from $65.00 to $79.00 and gave the stock an “overweight” rating in a research report on Friday, October 22nd. Zacks Investment Research downgraded shares of Progyny from a “hold” rating to a “sell” rating in a research report on Thursday. Finally, Jefferies Financial Group assumed coverage on shares of Progyny in a research report on Wednesday, December 1st. They set a “buy” rating and a $60.00 price target on the stock. One research analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, Progyny currently has a consensus rating of “Buy” and an average target price of $68.25.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Dark Forest Capital Management LP bought a new stake in Progyny in the second quarter worth approximately $32,000. Nisa Investment Advisors LLC bought a new stake in Progyny in the second quarter worth approximately $38,000. Atticus Wealth Management LLC bought a new stake in Progyny in the third quarter worth approximately $47,000. Harbor Investment Advisory LLC grew its position in Progyny by 67.7% in the third quarter. Harbor Investment Advisory LLC now owns 847 shares of the company’s stock worth $47,000 after acquiring an additional 342 shares in the last quarter. Finally, Greenspring Associates LLC bought a new stake in Progyny in the second quarter worth approximately $80,000. 90.52% of the stock is currently owned by hedge funds and other institutional investors.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.

See Also: Balance Sheet

Insider Buying and Selling by Quarter for Progyny (NASDAQ:PGNY)

Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.